Recent findings on the PD-1/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications.

Συγγραφείς: Ahmadi R; Department of Pathobiology, Faculty of Veterinary Medicine, Tabriz Medical Science, Islamic Azad University, Tabriz, Iran., Sadeghi KF; School of Medicine, Urmia University of Medical Sciences, Urmia, Iran; University of Medical Sciences, Department of Internal Medicine, School of Medicine, Urmia, Iran., Sharmsar O; School of Dentistry, Tabriz University of Medical Sciences, Islamic Azad University, Tabriz, Iran., Bagheri Y; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Dr.yasinbagheri@gmail.com., Sadeghi KF; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran., Koochehloghmani H; Department of Pathobiology, Faculty of Veterinary Medicine, Tabriz Medical Science, Islamic Azad University, Tabriz, Iran., Hoseinpourfeyzi M; Assistant Professor of Thoracic Surgery, Department of Cardiovascular Surgery, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Moeinpourfeyzi@gmail.com.

Πηγή: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2025 Dec; Vol. 216, pp. 104989. Date of Electronic Publication: 2025 Oct 25.

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): B7-H1 Antigen*/metabolism , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/immunology , Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Breast Neoplasms*/metabolism , Breast Neoplasms*/therapy , Breast Neoplasms*/immunology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Immunotherapy*/methods , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology, Humans ; Female ; Signal Transduction/drug effects ; Animals

rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy.

Συγγραφείς: Polcaro G; Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Liguori L; Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Manzo V; Clinical Pharmacology Unit, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., De Bellis E; Clinical Pharmacology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Stefanelli B; Clinical Pharmacology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Pagliara V; Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Langella M; Hematology and Transplant Unit, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Caputo A; Pathology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Ottaiano A; Structure of Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori di Napoli, IRCCS 'G. Pascale, Naples, Italy., Martinelli R; Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Cascella M; Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Ferrone C; Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA., Filippelli A; Clinical Pharmacology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Conti V; Clinical Pharmacology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Pepe S; Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy., Sabbatino F; Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy fsabbatino@unisa.it.

Πηγή: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Dec 04; Vol. 13 (12). Date of Electronic Publication: 2025 Dec 04.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Programmed Cell Death 1 Receptor*/genetics , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/metabolism , MicroRNAs*/genetics , MicroRNAs*/metabolism , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , B7-H1 Antigen*/antagonists & inhibitors , Immunotherapy*/adverse effects , Immunotherapy*/methods , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics, Humans ; Polymorphism, Single Nucleotide ; Female ; Male ; Middle Aged ; Aged

TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8 ⁺ T cells via lysosome-dependent degradation of TCF-1.

Συγγραφείς: Jiang P; Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Clinical Nutrition Department of Zhongshan Hospital, Fudan University, Shanghai 200000, China., Chen D; Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China., Chen J; Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China., Wu J; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China., Zhong Y; Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China., Huang S; Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China., Mu X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing 21000, China. Electronic address: mux@njmu.edu.cn., Lu X; Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Nanjing 21000, China. Electronic address: 189@whu.edu.cn., Wang X; Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Electronic address: wangxiaochen@mail.sysu.edu.cn.

Πηγή: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2025 Dec 03; Vol. 33 (12), pp. 6195-6211. Date of Electronic Publication: 2025 Sep 10.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE

Ιατρικοί όροι (MeSH): CD8-Positive T-Lymphocytes*/immunology , CD8-Positive T-Lymphocytes*/metabolism , Lysosomes*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/metabolism , Hepatocyte Nuclear Factor 1-alpha*/metabolism , Hepatocyte Nuclear Factor 1-alpha*/genetics , RNA, Long Noncoding*/genetics , T Cell Transcription Factor 1*/metabolism , T Cell Transcription Factor 1*/genetics , Neoplasms*/immunology , Neoplasms*/metabolism, Animals ; Mice ; Humans ; Cell Line, Tumor ; Proteolysis ; Immune Checkpoint Inhibitors/pharmacology

Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors.

Συγγραφείς: Yan H; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China., Wang Y; Institute of Structural Pharmacology & TCM Chemical Biology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China., Zhu M; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China., Sun D; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: sywysdj@163.com., Li H; Institute of Structural Pharmacology & TCM Chemical Biology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China. Electronic address: lihua@fjtcm.edu.cn., Chen L; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: syzyclx@163.com.

Πηγή: International immunopharmacology [Int Immunopharmacol] 2025 Dec 03; Vol. 166, pp. 115555. Date of Electronic Publication: 2025 Sep 16.

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/immunology , Neoplasms*/drug therapy , Neoplasms*/immunology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Drug Resistance, Neoplasm*/drug effects , Inflammation Mediators*, Humans ; Animals ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/immunology ; Drug Synergism ; Cytokines/metabolism

Physiological activation of Aryl hydrocarbon receptor by food-derived ligands is essential for the efficacy of anti-PD1 therapy.

Συγγραφείς: De Juan A; Institut Curie, PSL University, INSERM, U932, Paris, France., Coillard A; Institut Curie, PSL University, INSERM, U932, Paris, France., Cros A; Institut Curie, PSL University, INSERM, U932, Paris, France., Rigamonti A; Institut Curie, PSL University, INSERM, U932, Paris, France., Alaoui L; Institut Curie, PSL University, INSERM, U932, Paris, France., Sampaio JL; Institut Curie, PSL University, Plateforme de Métabolomique et Lipidomique, Paris, France., Monot N; Institut Curie, PSL University, INSERM, U932, Paris, France., Balvay A; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Foussier A; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Rieux-Laucat M; Institut Curie, PSL University, INSERM, U932, Paris, France., Guyonnet L; Institut Curie, PSL University, Plateforme de Cytométrie de Flux, Paris, France., Rabot S; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Vosshenrich C; Immunology Department, Institut Pasteur, INSERM, U1223, Innate Immunity Unit, Paris, France., Segura E; Institut Curie, PSL University, INSERM, U932, Paris, France. elodie.segura@inserm.fr.; Institut Necker Enfants Malades, INSERM, U1151, Paris, France. elodie.segura@inserm.fr.

Πηγή: Nature communications [Nat Commun] 2025 Dec 02; Vol. 16 (1), pp. 10598. Date of Electronic Publication: 2025 Dec 02.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Receptors, Aryl Hydrocarbon*/metabolism , Receptors, Aryl Hydrocarbon*/genetics , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/immunology , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use , Basic Helix-Loop-Helix Transcription Factors*/metabolism , Basic Helix-Loop-Helix Transcription Factors*/genetics, Animals ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/metabolism ; Mice ; Mice, Knockout ; Ligands ; Indoles/pharmacology ; Mice, Inbred C57BL ; Humans ; Diet ; Cell Line, Tumor ; Female ; Tryptophan/metabolism ; Killer Cells, Natural/immunology ; Neoplasms/immunology ; Neoplasms/drug therapy

Co-expression of PD1/PD-L1 on Tumor Cells Is Involved in the Regulation of Cell Proliferation.

Συγγραφείς: Nagasaki Y; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Yamane H; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan; hiromichi-y@med.kawasaki-m.ac.jp., Takeyama M; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.; Department of Internal Medicine, Okayama Suiseikai Hospital, Okayama, Japan., Ochi N; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Mimura A; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Kosaka Y; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Ichiyama N; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Kawahara T; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Nakanishi H; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan., Hiraki A; Department of Internal Medicine, Okayama Suiseikai Hospital, Okayama, Japan., Takigawa N; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.

Πηγή: Anticancer research [Anticancer Res] 2025 Dec; Vol. 45 (12), pp. 5341-5350.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE

Ιατρικοί όροι (MeSH): B7-H1 Antigen*/metabolism , B7-H1 Antigen*/genetics , Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/genetics, Humans ; Cell Proliferation/drug effects ; Cell Line, Tumor ; Signal Transduction/drug effects ; Nivolumab/pharmacology ; Interferon-gamma/pharmacology ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Gene Expression Regulation, Neoplastic/drug effects

Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1.

Συγγραφείς: Castellano KMG; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México., Luna AM; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México., de Jesús Carballo Uicab G; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México., Villedas FDR; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México., Rodríguez LJE; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México., Leyva SKV; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México., Luna SDR; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México., González EG; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México., Escalona MMP; SECIHTI-UDIBI, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México., Holland B; Antiverse Ltd., Cardiff, UK., Cristina PD; Antiverse Ltd., Cardiff, UK.; AstraZeneca, Biologics Engineering, Cambridge, UK., Santiago CR; Dirección de Investigación Científica Básica, Laboratorios Columbia SA de CV, Coyoacán, Mexico., Saldaña HAB; Dirección de Investigación Científica Básica, Laboratorios Columbia SA de CV, Coyoacán, Mexico., Tapia SMP; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; Laboratorio Nacional Para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) Para Farmoquímicos y Biotecnológicos, LANSEIDI-Farbiotec-CONACyT, Miguel Hidalgo, México.; Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México., Almagro JC; Unidad de Desarrollo e Investigación en Bioterapéuticos (UDIBI), Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Miguel Hidalgo, México.; GlobalBio, Inc., Cambridge, MA, USA.

Πηγή: MAbs [MAbs] 2025 Dec; Vol. 17 (1), pp. 2591461. Date of Electronic Publication: 2025 Nov 25.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Programmed Cell Death 1 Receptor*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Single-Chain Antibodies*/immunology , Single-Chain Antibodies*/pharmacology , Single-Chain Antibodies*/genetics , Immune Checkpoint Inhibitors*/pharmacology , Colonic Neoplasms*/immunology , Colonic Neoplasms*/drug therapy, Humans ; Animals ; Mice ; Mice, Transgenic ; Cell Line, Tumor

Synergistic Anticancer Effects of COL6A1 Downregulation and the PD1 Inhibitor Pembrolizumab in Bladder Cancer.

Συγγραφείς: Yuan F; Department of Outpatient, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou City, Zhejiang, China., Li X; Department of Information, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou City, Zhejiang, China., Hong C; Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou City, Zhejiang, China., Huang X; Department of Urology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou City, Zhejiang, China.

Πηγή: Journal of biochemical and molecular toxicology [J Biochem Mol Toxicol] 2025 Dec; Vol. 39 (12), pp. e70621.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Wiley Country of Publication: United States NLM ID: 9717231 Publication Model: Print Cited Medium: Internet ISSN: 1099-0461 (Electronic) Linking ISSN: 10956670 NLM ISO Abbreviation: J Biochem Mol Toxicol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Urinary Bladder Neoplasms*/pathology , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/metabolism , Urinary Bladder Neoplasms*/genetics , Antibodies, Monoclonal, Humanized*/pharmacology , Down-Regulation*/drug effects , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/metabolism , Collagen Type VI*/genetics , Collagen Type VI*/metabolism, Humans ; Animals ; Cell Line, Tumor ; Mice ; Cell Proliferation/drug effects ; Apoptosis/drug effects ; CD8-Positive T-Lymphocytes/metabolism ; Female ; Cell Movement/drug effects ; Male ; Xenograft Model Antitumor Assays

Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy.

Συγγραφείς: Jovanovic M; Department of Abdominal surgery, Military Medical Academy, Belgrade, Serbia.; Medical Faculty of the Military Medical, Academy University of Defense, Belgrade, Serbia., Gajovic N; Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Kragujevac, Serbia., Jocic M; Medical Faculty of the Military Medical, Academy University of Defense, Belgrade, Serbia.; Institute for Transfusiology and Haemobiology, Military Medical Academy, Belgrade, Serbia., Jovanovic M; Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Kragujevac, Serbia.; Department of Otorhinolaryngology, University of Kragujevac, Kragujevac, Serbia., Jurisevic M; Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Kragujevac, Serbia.; Department of Pharmacy, University of Kragujevac, Kragujevac, Serbia., Jovanovic I; Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Kragujevac, Serbia.; Department of Medicine, University of East Sarajevo, Foca, Bosnia and Herzegovina.

Πηγή: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2593198. Date of Electronic Publication: 2025 Nov 24.

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/immunology , Breast Neoplasms*/therapy , Breast Neoplasms*/drug therapy , Interleukin-33*/antagonists & inhibitors , Interleukin-33*/immunology , Interleukin-33*/metabolism , Interleukin-1 Receptor-Like 1 Protein*/antagonists & inhibitors , Interleukin-1 Receptor-Like 1 Protein*/immunology , Interleukin-1 Receptor-Like 1 Protein*/metabolism , Immunotherapy*/methods , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology, Humans ; Female ; Signal Transduction/drug effects ; Signal Transduction/immunology ; Tumor Microenvironment/immunology ; Tumor Microenvironment/drug effects ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Animals

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment.

Συγγραφείς: Huang FJ; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Fang YY; Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Wen JY; Department of Radiotherapy, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Li JJ; Department of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Lin Q; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Su QY; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Chen YY; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Wang L; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Zeng JJ; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Chi BT; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., He RQ; Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Qin DY; Department of Computer Science and Technology, School of Computer and Electronic Information, Guangxi University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China., Yang LH; Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China., Chen G; Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China.

Πηγή: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2444697. Date of Electronic Publication: 2025 Jan 06.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

Ιατρικοί όροι (MeSH): B7-H1 Antigen*/immunology , B7-H1 Antigen*/antagonists & inhibitors , Bile Duct Neoplasms*/immunology , Bile Duct Neoplasms*/mortality , Bile Duct Neoplasms*/therapy , Cholangiocarcinoma*/immunology , Cholangiocarcinoma*/mortality , Cholangiocarcinoma*/therapy , Immunotherapy*/methods , Programmed Cell Death 1 Receptor*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Tertiary Lymphoid Structures*/immunology , Bibliometrics*, Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Precision Medicine/methods ; Tumor Microenvironment/immunology

Targeting CREB1/p300-mediated RGS1 expression in tumor-associated macrophages improves the efficacy of anti-PD-1 therapy in triple-negative breast cancer.

Συγγραφείς: Liu X; Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao 266000 Shandong, China., Ju X; Pediatric Oncology Ward, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117 Shandong, China., Yuan R; Cancer Center, Public Health Clinical Center Affiliated to Shandong University, Shandong Public Health Clinical Center, Jinan 250100 Shandong, China., Pan B; Gynecology Department, Zouping City Center Hospital, Zouping 256200 Shandong, China., Feng T; Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117 Shandong, China., Ge J; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060 Guangdong, China., Wan M; School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau 999078 (or Macau SAR), China., Li X; Department of Gastroenterology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117 Shandong, China., Pan F; Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117 Shandong, China. Electronic address: pf4839@sd-cancer.com.

Πηγή: Biochemical pharmacology [Biochem Pharmacol] 2025 Dec; Vol. 242 (Pt 4), pp. 117395. Date of Electronic Publication: 2025 Oct 03.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): RGS Proteins*/genetics , RGS Proteins*/biosynthesis , RGS Proteins*/metabolism , RGS Proteins*/antagonists & inhibitors , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/metabolism , Triple Negative Breast Neoplasms*/genetics , Cyclic AMP Response Element-Binding Protein*/metabolism , Cyclic AMP Response Element-Binding Protein*/genetics , Cyclic AMP Response Element-Binding Protein*/antagonists & inhibitors , Tumor-Associated Macrophages*/metabolism , Tumor-Associated Macrophages*/drug effects , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/metabolism , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use , E1A-Associated p300 Protein*/metabolism , E1A-Associated p300 Protein*/genetics , E1A-Associated p300 Protein*/antagonists & inhibitors, Humans ; Animals ; Female ; Mice ; Cell Line, Tumor ; Xenograft Model Antitumor Assays/methods ; Gene Expression Regulation, Neoplastic/drug effects

Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 Immunotherapy.

Συγγραφείς: Arnouk SM; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Kancheva D; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium., Van Damme H; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Courtoy GE; Laboratory of Experimental Pathology (EXPA), Vrije Universiteit Brussel, Brussels, Belgium.; Department of Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Mora Barthelmess R; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Van Craenenbroeck J; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Lebegge E; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Elkrim Y; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Assaf N; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Heremans Y; Beta Cell Neogenesis Research Group (BENE), Genetics Reproduction and Development (GRAD), Vrije Universiteit Brussel, Brussels, Belgium.; Visual and Spatial Tissue Analysis (VSTA) Core Facility, Vrije Universiteit Brussel, Brussels, Belgium., Murgaski A; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium., De Groof TWM; Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium., Clappaert E; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium., Debraekeleer A; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium., Brughmans J; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium., Blancke G; Host-Microbiota Interaction Lab (HMI), VIB Center for Inflammation Research, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium., Kiss M; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.; Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium., Forsyth R; Laboratory of Experimental Pathology (EXPA), Vrije Universiteit Brussel, Brussels, Belgium.; Department of Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Waelput W; Laboratory of Experimental Pathology (EXPA), Vrije Universiteit Brussel, Brussels, Belgium.; Department of Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Boon L; JJP Biologics, Warsaw, Poland., Devoogdt N; Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium., Stortelers C; VIB Discovery Sciences, VIB, Ghent, Belgium., van Boxel N; VIB Discovery Sciences, VIB, Ghent, Belgium., Dombrecht B; VIB Discovery Sciences, VIB, Ghent, Belgium., Vereecke L; Host-Microbiota Interaction Lab (HMI), VIB Center for Inflammation Research, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium., Vincke C; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Raes G; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium., Laoui D; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium., Van Ginderachter JA; Lab of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium.

Πηγή: Cancer research [Cancer Res] 2025 Dec 01; Vol. 85 (23), pp. 4681-4700.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

Ιατρικοί όροι (MeSH): T-Lymphocytes, Regulatory*/immunology , T-Lymphocytes, Regulatory*/drug effects , T-Lymphocytes, Regulatory*/metabolism , Single-Domain Antibodies*/pharmacology , Single-Domain Antibodies*/immunology , Lymphocytes, Tumor-Infiltrating*/immunology , Lymphocytes, Tumor-Infiltrating*/drug effects , Lymphocytes, Tumor-Infiltrating*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Triple Negative Breast Neoplasms*/immunology , Triple Negative Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/therapy , Colorectal Neoplasms*/immunology , Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/therapy , Immune Checkpoint Inhibitors*/pharmacology, Animals ; Humans ; Mice ; Tumor Microenvironment/immunology ; Immunotherapy/methods ; Female ; Antibody-Dependent Cell Cytotoxicity/immunology ; Cell Line, Tumor

PD-1 Attenuates Neuropathic Pain by Ameliorating NLRP3 Inflammasome-Mediated Microglia Pyroptosis.

Συγγραφείς: Deng D; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Ma L; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Shen J; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Huang L; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Zhang T; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Yang X; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Huang S; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Zhao W; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Zhou Y; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Fan S; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Wang K; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China., Chen X; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China. xdchen@hust.edu.cn.; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. xdchen@hust.edu.cn.; Key Laboratory of Anesthesiology and Resuscitation, Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430022, China. xdchen@hust.edu.cn.

Πηγή: Molecular neurobiology [Mol Neurobiol] 2025 Dec; Vol. 62 (12), pp. 15478-15493. Date of Electronic Publication: 2025 Jul 19.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Humana Press Country of Publication: United States NLM ID: 8900963 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-1182 (Electronic) Linking ISSN: 08937648 NLM ISO Abbreviation: Mol Neurobiol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): NLR Family, Pyrin Domain-Containing 3 Protein*/metabolism , Pyroptosis*/drug effects , Pyroptosis*/physiology , Microglia*/metabolism , Microglia*/drug effects , Microglia*/pathology , Neuralgia*/metabolism , Neuralgia*/pathology , Neuralgia*/drug therapy , Inflammasomes*/metabolism , Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors, Animals ; Male ; Mice, Inbred C57BL ; NF-kappa B/metabolism ; Mice ; Signal Transduction/drug effects ; Sulfones/pharmacology ; Spinal Cord/metabolism ; Spinal Cord/pathology ; Furans ; Indenes ; Sulfonamides

Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model.

Συγγραφείς: Lamenza FF; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Roth P; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Upadhaya P; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Shrestha S; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Jagadeesha S; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Kazmierowicz N; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Horn N; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Pracha H; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Dasari S; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Oghumu S; Department of Pathology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Πηγή: Oncoimmunology [Oncoimmunology] 2025 Dec; Vol. 14 (1), pp. 2477872. Date of Electronic Publication: 2025 Mar 17.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use , Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/immunology , Squamous Cell Carcinoma of Head and Neck*/pathology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/immunology , Head and Neck Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Animals ; Mice ; Lymphocyte Activation Gene 3 Protein ; Disease Models, Animal ; Humans ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/drug effects ; Cell Line, Tumor ; Tumor Microenvironment/drug effects

Photodynamic-Immunotherapy Synergy: Decoding the Spatiotemporal Regulation of Tumour Immunogenicity for Enhanced PD-1 Blockade.

Συγγραφείς: ChenLiu Z; Clinical Medical College, Yangzhou University, Yangzhou, China., Wang L; Clinical Medical College, Yangzhou University, Yangzhou, China., Gu C; Clinical Medical College, Yangzhou University, Yangzhou, China., Tang D; Department of General Surgery, Institute of General Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.; Northern Jiangsu People's Hospital, Yangzhou, China.; The Yangzhou Clinical Medical College of Xuzhou Medical University, Yangzhou, China.; The Yangzhou School of Clinical Medicine of Dalian Medical University, Yangzhou, China.; The Yangzhou School of Clinical Medicine of Nanjing Medical University, Yangzhou, China.; Northern Jiangsu People's Hospital, Clinical Teaching Hospital of Medical School, Nanjing University, Yangzhou, China.

Πηγή: Immunology [Immunology] 2025 Dec; Vol. 176 (4), pp. 438-453. Date of Electronic Publication: 2025 Oct 08.

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0374672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2567 (Electronic) Linking ISSN: 00192805 NLM ISO Abbreviation: Immunology Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Photochemotherapy*/methods , Neoplasms*/immunology , Neoplasms*/therapy , Neoplasms*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Immunotherapy*/methods, Humans ; Tumor Microenvironment/immunology ; Tumor Microenvironment/drug effects ; Animals ; Photosensitizing Agents/therapeutic use ; Combined Modality Therapy ; Immunogenic Cell Death/drug effects ; Reactive Oxygen Species/metabolism ; T-Lymphocytes/immunology ; T-Lymphocytes/drug effects

Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.

Συγγραφείς: Yang Y; Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; College of Medicine, Linyi University, Linyi 276000, China., Xu M; Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China., Wang K; Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China., Xia L; Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China., Ning Q; Department of Pharmacology, State Key laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China., Wu X; Department of Pharmacology, State Key laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China., Zang X; College of Medicine, Linyi University, Linyi 276000, China., Lai F; Department of Pharmacology, State Key laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address: laifangfang@imm.ac.cn., Chen X; Department of Pharmacology, State Key laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address: chxg@imm.ac.cn., Feng Z; Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China. Electronic address: fengzhq@imm.ac.cn.

Πηγή: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2025 Dec 01; Vol. 130, pp. 118366. Date of Electronic Publication: 2025 Aug 19.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Elsevier Science Country of Publication: England NLM ID: 9413298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3391 (Electronic) Linking ISSN: 09680896 NLM ISO Abbreviation: Bioorg Med Chem Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , B7-H1 Antigen*/metabolism , B7-H1 Antigen*/antagonists & inhibitors , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis , Phenyl Ethers*/chemistry , Phenyl Ethers*/pharmacology , Phenyl Ethers*/chemical synthesis , Drug Discovery* , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/chemistry , Immune Checkpoint Inhibitors*/chemical synthesis, Humans ; Animals ; Structure-Activity Relationship ; Mice ; Molecular Structure ; Drug Screening Assays, Antitumor ; Dose-Response Relationship, Drug ; Molecular Docking Simulation ; Cell Proliferation/drug effects ; Cell Line, Tumor ; Protein Binding/drug effects

Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content.

Συγγραφείς: Luo B; Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China.; Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, P.R. China., An Q; Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China., Lei J; School of Basic Medicine, Medical College of Yan'an University, Yan'an, P.R. China., Tan D; Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China., Liu X; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, P.R. China., Li H; School of Basic Medicine, Medical College of Yan'an University, Yan'an, P.R. China., Zhao Y; Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China., Qin J; Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China., Zhang C; Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China., Zhang Y; Laboratory Animal Center, Guangzhou University of Chinese Medicine, Guangzhou, P.R. China., Shi C; Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China.

Πηγή: Gut microbes [Gut Microbes] 2025 Dec; Vol. 17 (1), pp. 2447821. Date of Electronic Publication: 2024 Dec 30.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101495343 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1949-0984 (Electronic) Linking ISSN: 19490976 NLM ISO Abbreviation: Gut Microbes Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Gastrointestinal Microbiome*/drug effects , Resveratrol*/pharmacology , Prostaglandin D2*/metabolism , Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors, Animals ; Mice ; Humans ; Cell Line, Tumor

Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis.

Συγγραφείς: Chen S; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Xu C; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Liu C; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Li J; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Ke S; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Lu Y; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Huang Y; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Chen J; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Lin F; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Huang H; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China., Zou Z; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Institute of Clinical Neurology, Fujian Medical University, Fuzhou, China.; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou, China.

Πηγή: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2540023. Date of Electronic Publication: 2025 Aug 03.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Amyotrophic Lateral Sclerosis*/immunology , Amyotrophic Lateral Sclerosis*/blood , Amyotrophic Lateral Sclerosis*/diagnosis , Programmed Cell Death 1 Receptor*/blood , Programmed Cell Death 1 Receptor*/immunology , Immune Checkpoint Proteins*/blood, Humans ; Male ; Female ; Middle Aged ; Prognosis ; Disease Progression ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; Aged ; Biomarkers/blood ; Neurofilament Proteins/blood ; Adult ; Case-Control Studies ; Flow Cytometry

Molecular mechanisms and potential targeting strategies of ubiquitin‑proteasome system‑mediated PD‑1/PD‑L1 ubiquitination in tumor immune suppression (Review).

Συγγραφείς: Gu LH; Department of Diagnostic Pathology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China., Guo A; Department of Diagnostic Pathology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China., Ding YY; Department of Diagnostic Pathology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China., Wang XJ; Department of Diagnostic Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang 312000, P.R. China., Zhang HX; Department of Diagnostic Pathology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China., Duan WL; Medical Research Center, Shaoxing People's Hospital, Shaoxing, Zhejiang 312000, P.R. China., Zhang BG; Department of Diagnostic Pathology, School of Basic Medical Sciences, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.

Πηγή: Oncology reports [Oncol Rep] 2025 Dec; Vol. 54 (6). Date of Electronic Publication: 2025 Oct 03.

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE

Ιατρικοί όροι (MeSH): B7-H1 Antigen*/metabolism , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/immunology , Neoplasms*/immunology , Neoplasms*/drug therapy , Neoplasms*/pathology , Neoplasms*/metabolism , Proteasome Endopeptidase Complex*/metabolism , Proteasome Endopeptidase Complex*/immunology , Ubiquitin*/metabolism , Programmed Cell Death 1 Receptor*/metabolism , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/immunology , Tumor Escape*/drug effects , Tumor Escape*/immunology , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use, Humans ; Ubiquitination/drug effects ; Ubiquitination/immunology ; Tumor Microenvironment/immunology ; Tumor Microenvironment/drug effects ; Animals ; Signal Transduction/drug effects ; Signal Transduction/immunology ; Immunotherapy/methods ; Drug Resistance, Neoplasm/immunology ; Drug Resistance, Neoplasm/drug effects

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.

Συγγραφείς: Tuergan T; Hepatobiliary and Echinococcosis Surgery Department, Digestive and Vascular Surgery Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China., Abulaiti A; Hepatobiliary and Echinococcosis Surgery Department, Digestive and Vascular Surgery Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China., Shao Y; Hepatobiliary and Echinococcosis Surgery Department, Digestive and Vascular Surgery Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China., Aji T; Hepatobiliary and Echinococcosis Surgery Department, Digestive and Vascular Surgery Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Πηγή: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2540143. Date of Electronic Publication: 2025 Aug 17.

Τύπος έκδοσης: Historical Article; Journal Article

Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

Ιατρικοί όροι (MeSH): B7-H1 Antigen*/immunology , B7-H1 Antigen*/antagonists & inhibitors , Carcinoma, Hepatocellular*/therapy , Carcinoma, Hepatocellular*/immunology , Immune Checkpoint Inhibitors*/therapeutic use , Immunotherapy*/methods , Immunotherapy*/trends , Immunotherapy*/history , Liver Neoplasms*/therapy , Liver Neoplasms*/immunology , Programmed Cell Death 1 Receptor*/immunology , Programmed Cell Death 1 Receptor*/antagonists & inhibitors, Humans ; Bibliometrics ; History, 20th Century ; History, 21st Century ; Review Literature as Topic